| Completed | 1 | 31 | US | AT13387 | National Cancer Institute (NCI) | Solid Tumors, Breast Cancer | 12/13 | 10/17 | | |
NCT02627430: Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer |
|
|
| Withdrawn | 1 | 0 | US | Hsp90 Inhibitor AT13387, AT13387, Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib, BMN 673, BMN-673 | National Cancer Institute (NCI) | Adult Solid Neoplasm, Estrogen Receptor Negative, Fallopian Tube Serous Neoplasm, HER2/Neu Negative, Ovarian Serous Adenocarcinoma, Ovarian Serous Tumor, Primary Peritoneal Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Triple-Negative Breast Carcinoma | 03/19 | | | |
